Kate is a Senior Analyst at Asymmetry Group supporting clients across rare disease commercialization and launch strategy engagements. Her work focuses on helping teams prepare for launch by translating complex clinical, customer, and market dynamics into actionable commercial strategies.
Kate has contributed to launch planning across a broad range of rare disease programs, supporting strategy development, execution planning, and launch readiness activities. She brings strong analytical rigor and cross-functional coordination skills that help teams move efficiently from strategic planning to execution.
Kate holds a Bachelor of Arts degree, summa cum laude, in Business Management and French Studies from Washington College.
